Head and Neck Cancers Coverage from Every Angle

Recent News

ASTRO 2019: Adding Cisplatin to Radiation Therapy in Advanced Oropharyngeal Cancer
ASTRO 2019: Can Taking Aspiring During Chemoradiotherapy Improve Outcomes in Head/Neck Cancer?
ASTRO 2019: Circulating Tumor DNA and Survival in HPV-Positive Oropharyngeal Cancer
ASTRO 2019: Predicting Radiation Toxicity in Head/Neck Cancer With Machine-Learning Model
Does Cigarette Smoke Prompt Head and Neck Cancer Aggressiveness?
Quality Care 2019: Hearing Screening After Treatment for Head and Neck Cancers
Radiotherapy Versus Surgery in Oropharyngeal Cancer: Quality of Life From ORATOR Trial
Adding Nimotuzumab to Chemoradiotherapy in Locally Advanced Head and Neck Cancer
Adding Palbociclib to Cetuximab in Platinum-Resistant Head and Neck Cancer
Novel Monoclonal Antibody Plus Cetuximab Under Study in Head/Neck Cancer
Statin Use After Radiotherapy for Head and Neck Cancer Survivors
FDA Approves Pembrolizumab in PD-L1–Expressing Squamous Cell Carcinoma of the Esophagus
Differentiating Treatment Levels for HPV-Linked Oropharyngeal Cancer
RNA Sequencing Reveals Alternative Splicing in Some Head and Neck Cancers
Checkpoint Inhibitors in Oropharyngeal Cancer: Window-of-Opportunity Trial
First Clinical Immunotherapy Treatment Guidelines for Squamous Cell Carcinoma of the Head and Neck
New Chemoradiotherapy Formulation for Head and Neck Tumors May Reduce Toxicity, Preclinical Study Finds
Risk Factors for Intracranial Aneurysms After Radiotherapy for Head and Neck Cancer
Taxane Versus Fluorouracil: Comparing First-Line Regimens in Head and Neck Cancer
EAGLE Trial: Novel Immunotherapies for Resistant Head/Neck Cancer
Proton Therapy Versus Conventional Photon Therapy in Locally Advanced Cancer
ASCO 2019: Induction Chemotherapy Followed by Chemoradiotherapy in Nasopharyngeal Cancer
Fox Chase Researcher Shares NIH Grant to Study Palliative Care in Head and Neck Cancer
ASCO 2019: Targeting Resistant Adenoid Cystic Carcinoma With Apatinib
ASCO 2019: Phase II Basket Trial of T-DM1 in Salivary Gland Cancers
Pembrolizumab Approved for First-Line Treatment of Head and Neck Squamous Cell Carcinoma
ASCO 2019: Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Head and Neck Cancer
Forecasting Trends in Oropharyngeal Cancer in the United States
ASCO 2019: First-Line Pembrolizumab for Metastatic Head/Neck Cancer
Use of Acetylcysteine for Cisplatin-Induced Toxicities in Head and Neck Cancer
FDA Grants Orphan Drug Designation for AL101 in Adenoid Cystic Carcinoma
Alternative Chemotherapy Regimen to Cisplatin in Locally Advanced Head/Neck Cancer
Potential Applications of Machine Learning and Radiomics in Head and Neck Cancers
NIH Releases Latest PDQ Cancer Information Summary on Head and Neck Cancers
Phase II Study of Lenvatinib in Recurrent or Metastatic Adenoid Cystic Carcinoma
Mount Sinai Begins Clinical Trials in Head and Neck Cancers

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.